{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:05:38Z","timestamp":1779192338229,"version":"3.51.4"},"reference-count":46,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2026.0055","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:05:56Z","timestamp":1779188756000},"source":"Crossref","is-referenced-by-count":0,"title":["The effects of new antidiabetic drugs on the course of peripheral arterial occlusive disease"],"prefix":"10.3238","author":[{"given":"Knut","family":"Kr\u00f6ger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hinrich","family":"B\u00f6hner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian-Alexander","family":"Behrendt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"von Beckerath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11437","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"10.3238\/arztebl.m2026.0055_ref1","doi-asserted-by":"crossref","unstructured":"Azhar A, Basheer M, Abdelgawad MS, Roshdi H, Kamel MF: Prevalence of peripheral arterial disease in diabetic foot ulcer patients and its impact in limb salvage. Int J Low Extrem Wounds 2023; 22: 518\u201323","DOI":"10.1177\/15347346211027063"},{"key":"10.3238\/arztebl.m2026.0055_ref2","doi-asserted-by":"crossref","unstructured":"Egen C, B\u00f6kel A, Gro\u00dfhennig A, Ernst J, Sturm C, Schiller J: The changing rates of lower-limb amputations in Germany: An analysis of data from the Federal Statistical Office, 2005\u20132023. Dtsch Arztebl Int 2025; 122: 449\u201350","DOI":"10.3238\/arztebl.m2025.0104"},{"key":"10.3238\/arztebl.m2026.0055_ref3","doi-asserted-by":"crossref","unstructured":"Chan HWE, Ashan B, Jayasekera P, Collier A, Ghosh S: A new class of drug for the management of type 2 diabetes: Sodium glucose co-transporter inhibitors: \u201aglucuretics\u2018. Diabetes Metab Syndr 2012; 6: 224\u20138","DOI":"10.1016\/j.dsx.2012.08.003"},{"key":"10.3238\/arztebl.m2026.0055_ref4","doi-asserted-by":"crossref","unstructured":"Poulsen SB, Fenton RA, Rieg T: Sodium-glucose cotransport. Curr Opin Nephrol Hypertens 2015; 24: 463\u20139","DOI":"10.1097\/MNH.0000000000000152"},{"key":"10.3238\/arztebl.m2026.0055_ref5","doi-asserted-by":"crossref","unstructured":"Zannad F, Ferreira JP, Pocock SJ, et al.: SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: A meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 2020; 396 (10254): 819\u201329","DOI":"10.1016\/S0140-6736(20)31824-9"},{"key":"10.3238\/arztebl.m2026.0055_ref6","doi-asserted-by":"crossref","unstructured":"Shaffner J, Chen B, Malhotra DK, Dworkin LD, Gong R: Therapeutic targeting of SGLT2: A new era in the treatment of diabetes and diabetic kidney disease. Front Endocrinol (Lausanne) 2021; 12: 749010","DOI":"10.3389\/fendo.2021.749010"},{"key":"10.3238\/arztebl.m2026.0055_ref7","doi-asserted-by":"crossref","unstructured":"Gao M, Bhatia K, Kapoor A, et al.: SGLT2 inhibitors, functional capacity, and quality of life in patients with heart failure: A systematic review and meta-analysis. JAMA Netw Open 2024; 7: e245135","DOI":"10.1001\/jamanetworkopen.2024.5135"},{"key":"10.3238\/arztebl.m2026.0055_ref8","doi-asserted-by":"crossref","unstructured":"McKay NJ, Kanoski SE, Hayes MR, Daniels D: Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake. Am J Physiol Regul Integr Comp Physiol 2011; 301: R1755\u201364","DOI":"10.1152\/ajpregu.00472.2011"},{"key":"10.3238\/arztebl.m2026.0055_ref9","doi-asserted-by":"crossref","unstructured":"Winzeler B, da Concei\u00e7\u00e3o I, Refardt J, Sailer CO, Dutilh G, Christ-Crain M: Effects of glucagon-like peptide-1 receptor agonists on fluid intake in healthy volunteers. Endocrine 2020; 70: 292\u20138","DOI":"10.1007\/s12020-020-02394-2"},{"key":"10.3238\/arztebl.m2026.0055_ref10","doi-asserted-by":"crossref","unstructured":"Lee MMY, Sattar N, Pop-Busui R, et al.: Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: A systematic review and meta-analysis of randomized trials. Diabetes Care 2025; 48: 846\u201359","DOI":"10.2337\/dc25-0241"},{"key":"10.3238\/arztebl.m2026.0055_ref11","unstructured":"Nauck M: Perspektiven der Diabetologie: Inkretin-Agonisten: In 30 Jahren vom Geheimtipp zum Bestseller."},{"key":"10.3238\/arztebl.m2026.0055_ref12","unstructured":"AWMF: S3-Leitlinie zur Diagnostik, Therapie und Nachsorge der peripheren arteriellen Verschlusskrankheit. AWMF-Register Nr. 065\/003, Version 4.1 vom 10.10.2024."},{"key":"10.3238\/arztebl.m2026.0055_ref13","doi-asserted-by":"crossref","unstructured":"Buso G, Hersant J, Keller S, et al.: Cutting-edge European guidelines for managing lower extremity peripheral arterial disease\u2014featuring selected insights on PAD management. Vasa 2025; 54: 225\u201334","DOI":"10.1024\/0301-1526\/a001186"},{"key":"10.3238\/arztebl.m2026.0055_ref14","doi-asserted-by":"crossref","unstructured":"Rodionov RN, Frederik Peters F, Marschall U, L\u2019Hoest H, Jarzebska N, Behrendt CA: Initiation of SGLT2 inhibitors and the risk of lower extremity minor and major amputation in patients with type 2 diabetes and peripheral arterial disease: A health claims data analysis. Eur J Vasc Endovasc Surg 2021; 62: 981\u201390","DOI":"10.1016\/j.ejvs.2021.09.031"},{"key":"10.3238\/arztebl.m2026.0055_ref15","doi-asserted-by":"crossref","unstructured":"Marchiori E, Rodionov RN, Peters F, et al.: SGLT2 inhibitors and peripheral vascular events\u2014a review of the literature. Heart Failure Clin 2022; 18: 609\u201323","DOI":"10.1016\/j.hfc.2022.03.001"},{"key":"10.3238\/arztebl.m2026.0055_ref16","doi-asserted-by":"crossref","unstructured":"Fitridge R, Chuter V, Mills J, et al.: The intersocietal IWGDF, ESVS, SVS guidelines on peripheral artery disease in people with diabetes and a foot ulcer. Diabetes Metab Res Rev 2024; 40: e3686","DOI":"10.1002\/dmrr.3686"},{"key":"10.3238\/arztebl.m2026.0055_ref17","doi-asserted-by":"crossref","unstructured":"Geng L, Sun B, Chen Y: A meta-analysis of randomized controlled studies examining the effects of sodium-glucose co-transporter-2 inhibitors on peripheral artery disease and risk of amputations. Diabetes Obes Metab 2024; 26: 5376\u201389","DOI":"10.1111\/dom.15901"},{"key":"10.3238\/arztebl.m2026.0055_ref18","doi-asserted-by":"crossref","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al.: Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644\u201357","DOI":"10.1056\/NEJMoa1611925"},{"key":"10.3238\/arztebl.m2026.0055_ref19","doi-asserted-by":"crossref","unstructured":"Matthews DR, Li Q, Perkovic V, et al.: Effects of canagliflozin on amputation risk in type 2 diabetes: The CANVAS Program. Diabetologia 2019; 62: 926\u201338","DOI":"10.1007\/s00125-019-4839-8"},{"key":"10.3238\/arztebl.m2026.0055_ref20","doi-asserted-by":"crossref","unstructured":"Perkovic V, Jardine MJ, Neal B, et al.: Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380: 2295\u2013306","DOI":"10.1056\/NEJMoa1811744"},{"key":"10.3238\/arztebl.m2026.0055_ref21","doi-asserted-by":"crossref","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, et al.: Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 2020; 383: 1425\u201335","DOI":"10.1056\/NEJMoa2004967"},{"key":"10.3238\/arztebl.m2026.0055_ref22","doi-asserted-by":"crossref","unstructured":"Packer M, Anker SD, Butler J, et al.: Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020; 383: 1413\u201324","DOI":"10.1056\/NEJMoa2022190"},{"key":"10.3238\/arztebl.m2026.0055_ref23","doi-asserted-by":"crossref","unstructured":"Anker SD, Butler J, Filippatos G, et al.: Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021; 385: 1451\u201361","DOI":"10.1056\/NEJMoa2107038"},{"key":"10.3238\/arztebl.m2026.0055_ref24","doi-asserted-by":"crossref","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al.: Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381: 1995\u20132008","DOI":"10.1056\/NEJMoa1911303"},{"key":"10.3238\/arztebl.m2026.0055_ref25","doi-asserted-by":"crossref","unstructured":"Herrington WG, Staplin N, Wanner C, et al.: Empagliflozin in patients with chronic kidney disease. N Engl J Med 2023; 388: 117\u201327","DOI":"10.1056\/NEJMoa2204233"},{"key":"10.3238\/arztebl.m2026.0055_ref26","doi-asserted-by":"crossref","unstructured":"Liarakos AL, Tentolouris A, Kokkinos A, Eleftheriadou I, Tentolouris N: Impact of glucagon-like peptide 1 receptor agonists on peripheral arterial disease in people with diabetes mellitus: A narrative review. J Diabetes Complications 2023; 37: 108390","DOI":"10.1016\/j.jdiacomp.2022.108390"},{"key":"10.3238\/arztebl.m2026.0055_ref27","doi-asserted-by":"crossref","unstructured":"Caruso P, Maiorino MI, Longo M, et al.: Liraglutide for lower limb perfusion in people with type 2 diabetes and peripheral artery disease: The STARDUST randomized clinical trial. JAMA Netw Open 2024; 7: e241545","DOI":"10.1001\/jamanetworkopen.2024.1545"},{"key":"10.3238\/arztebl.m2026.0055_ref28","doi-asserted-by":"crossref","unstructured":"No authors listed: Error in table and results. JAMA Netw Open 2025; 8: e2547627","DOI":"10.1001\/jamanetworkopen.2025.47627"},{"key":"10.3238\/arztebl.m2026.0055_ref29","doi-asserted-by":"crossref","unstructured":"Go CC, Annie F, Drabish K, Eslami MH: Glucagon-like peptide-1 receptor agonists are associated with fewer major adverse cardiovascular and limb events in patients with moderate peripheral arterial disease. J Vasc Surg 2025; 82: 1024\u201332.e2","DOI":"10.1016\/j.jvs.2025.05.037"},{"key":"10.3238\/arztebl.m2026.0055_ref30","doi-asserted-by":"crossref","unstructured":"Daniel E, El-Nayir M, Ogunniyi K, et al.: Impact of GLP-1 receptor agonists on cardiovascular outcomes in patients with peripheral artery disease without diabetes: A propensity score-matched analysis. J Investig Med 2025: 10815589251393978","DOI":"10.1177\/10815589251393978"},{"key":"10.3238\/arztebl.m2026.0055_ref31","doi-asserted-by":"crossref","unstructured":"Bonaca MP, Catarig AM, Houlind K, et al.: Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): A phase 3b, double-blind, randomised, placebo-controlled trial. Lancet 2025; 405: 1580\u201393","DOI":"10.1016\/S0140-6736(25)00509-4"},{"key":"10.3238\/arztebl.m2026.0055_ref32","doi-asserted-by":"crossref","unstructured":"Rasouli N, Arslan EG, Catarig AM, et al.: Benefit of semaglutide in symptomatic peripheral artery disease by baseline type 2 diabetes characteristics: Insights from STRIDE, a randomized, placebo-controlled, double-blind trial. Diabetes Care 2025; 48: 1529\u201335","DOI":"10.2337\/dc25-1082"},{"key":"10.3238\/arztebl.m2026.0055_ref33","doi-asserted-by":"crossref","unstructured":"Verma S, Catarig AM, Houlind K, et al.: Sex differences in effectiveness of semaglutide in patients with peripheral artery disease: The STRIDE trial. J Am Coll Cardiol 2025; 86: 1843\u201357","DOI":"10.1016\/j.jacc.2025.08.046"},{"key":"10.3238\/arztebl.m2026.0055_ref34","unstructured":"Sourij H, Guder Arslan E, Catarig AM, et al.: Improvement in walking distance with semaglutide in smokers with peripheral artery disease: STRIDE trial subgroup analysis. J Am Coll Cardiol 2025: S0735\u20131097(25)10168-X."},{"key":"10.3238\/arztebl.m2026.0055_ref35","doi-asserted-by":"crossref","unstructured":"McGuire DK, Marx N, Mulvagh SL, et al.: Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N Engl J Med 2025; 392: 2001\u201312","DOI":"10.1056\/NEJMoa2501006"},{"key":"10.3238\/arztebl.m2026.0055_ref36","doi-asserted-by":"crossref","unstructured":"Shuja SH, Shuja MH, Shaukat A, et al.: GLP-1 receptor agonists and cardiovascular outcomes in adults with diabetes and peripheral artery disease: An updated systematic review and meta-analysis. Am J Cardiol 2026; 258: 268\u201375.","DOI":"10.1016\/j.amjcard.2025.09.039"},{"key":"10.3238\/arztebl.m2026.0055_ref37","doi-asserted-by":"crossref","unstructured":"Badjatiya A, Merrill P, Buse JB, et al.: Clinical outcomes in patients with type 2 diabetes mellitus and peripheral artery disease: Results from the EXSCEL trial. Circ Cardiovasc Interv 2019; 12: e008018","DOI":"10.1161\/CIRCINTERVENTIONS.119.008018"},{"key":"10.3238\/arztebl.m2026.0055_ref38","doi-asserted-by":"crossref","unstructured":"Dutta D, Mahajan K, Kamrul-Hasan ABM, Mahajan N, Sharma M, Vohra S: Impact of glucagon-like peptide-1 receptor agonism-based therapies on limb outcomes in peripheral artery disease and type 2 diabetes: An updated systematic review and meta-analysis. Diabetes Obes Metab 2026; 28: 2075\u201384","DOI":"10.1111\/dom.70391"},{"key":"10.3238\/arztebl.m2026.0055_ref39","doi-asserted-by":"crossref","unstructured":"Hong AT, Lin F, Luu IY, et al.: Risk of lower extremity complications with GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-4 inhibitors in peripheral artery disease. Diabetes Res Clin Pract 2025; 230: 112982","DOI":"10.1016\/j.diabres.2025.112982"},{"key":"10.3238\/arztebl.m2026.0055_ref40","doi-asserted-by":"crossref","unstructured":"Giugliano D, Longo M, Di Martino N, et al.: GLP1\u20131RAs improve walking distance and reduce amputation in people with type 2 diabetes and peripheral artery disease: A systematic review and meta-analysis of randomised controlled trials and cohort studies. Diabetes Obes Metab 2026; 28: 2775\u201383","DOI":"10.1111\/dom.70454"},{"key":"10.3238\/arztebl.m2026.0055_ref41","doi-asserted-by":"crossref","unstructured":"Aronis KN, Chamberland JP, Mantzoros CS: GLP-1 promotes angiogenesis in human endothelial cells in a dose-dependent manner, through the Akt, Src and PKC pathways. Metabolism 2013; 62: 1279\u201386","DOI":"10.1016\/j.metabol.2013.04.010"},{"key":"10.3238\/arztebl.m2026.0055_ref42","doi-asserted-by":"crossref","unstructured":"Tanaka A, Node K: Increased amoutation risk with canaglifozin treatment: Behind the large cardiovascular benefit? Cardiovasc Diabetol 2017; 16: 129","DOI":"10.1186\/s12933-017-0611-x"},{"key":"10.3238\/arztebl.m2026.0055_ref43","doi-asserted-by":"crossref","unstructured":"Ferrannini E, Muscelli E, Franscerra S: Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014; 124: 499\u2013508","DOI":"10.1172\/JCI72227"},{"key":"10.3238\/arztebl.m2026.0055_ref44","doi-asserted-by":"crossref","unstructured":"Barraclough JY, Yu J, Figtree GA, et al.: Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial. Diabetes Obes Metab 2022; 24: 1072\u201383","DOI":"10.1111\/dom.14671"},{"key":"10.3238\/arztebl.m2026.0055_ref45","doi-asserted-by":"crossref","unstructured":"Holman RR, Bethel MA, Mentz RJ, et al.: Effects of once weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017; 377: 1228\u201339","DOI":"10.1056\/NEJMoa1612917"},{"key":"10.3238\/arztebl.m2026.0055_ref46","doi-asserted-by":"crossref","unstructured":"Marso SP, Bain SC, Consoli A, et al.: Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375: 1834\u201344","DOI":"10.1056\/NEJMoa1607141"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2026.0055","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:06:33Z","timestamp":1779188793000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2026.0055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":46,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2026.0055","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]}}}